Pedi QuikCalc 5 is a specialized medical calculator for pediatricians and family medicine practitioners on iOS.
The App DNA
What makes this app unique?
It removes the cognitive friction of manual weight-based drug dosing and nomogram plotting during high-pressure clinical encounters.
For Pediatricians and family medicine practitioners requiring rapid, weight-based clinical calculations.
What does it look like?
Key features
Calculates drug dosages and IV fluid rates based on patient weight inputs, establishing category authority.
Plots bilirubin levels against AAP thresholds, justifying the one-time purchase price.
Pushes updated dosing guidelines automatically, preventing churn from outdated medical data.
How much does it cost?
The $4.99 price point targets professional users seeking a specialized, ad-free clinical utility.
Velocity
Dormant developmentperformanceShow more...
Pedi QuikCalc 5 shows no signs of active development, with only two releases identified in the available history. The latest release occurred 398 days ago, placing the app well beyond the threshold for a zombie classification. Development has been stagnant for over a year, with no evidence of new features or ongoing maintenance.
Who built it?
User Sentiment
What do users think recently?
How are ratings & reviews evolving?
Not enough recent reviews to extract reliable themes yet.
Read the full review analysisCompetition
Competitive landscape for Pedi QuikCalc 5
How's the Medical market?
Pedi QuikCalc 5 holds the #13 Paid position in the US Medical category. The app's reliance on a one-time purchase model at $4.99 contrasts with the broader category shift toward subscription-based, frequently updated medical references.
Read the market outlookThe rivals identified
By Skyscape
Offers comprehensive clinical decision support and dosage calculators for pediatric professionals.
Pedi QuikCalc 5 vs Village Health: Pediatric Care
PedsGuideNemesis
epocrates: Drug Info & Pill IDContenderPPediSTAT - Pediatric EmergencyNemesisMMedCalcXContenderQQxMD CalculateContenderUnlock the deeper market read.
Access the full report for freeThe Analyst's Read
Key takeaways for Pedi QuikCalc 5
Where is it heading?
The market for medical reference tools is shifting toward subscription-based, frequently updated platforms that integrate with electronic health records. Pedi QuikCalc 5 remains a trusted, specialized tool, but its current maintenance-only cadence risks long-term obsolescence as clinical standards evolve.
- The app maintains a strong #13 Paid rank in the US, indicating high professional trust in its core clinical accuracy.
- The 398-day gap since the last major update signals a maintenance-only posture, which limits the ability to respond to new clinical guidelines.
The SWOT
- Specialized bilirubin nomogram tool establishes clinical authority
- Customizable home screen reduces time-to-task for clinicians
- Automatic formulary updates ensure long-term clinical utility
- Localized pricing in high-ARPU international markets
- Expansion of formulary to include emerging pediatric specialty guidelines
- Integration with common electronic health record workflows
Next best moves
Audit drug formulary update logic because the app relies on this to maintain clinical relevance → prevent churn from outdated data
+ 1 more prioritized moveThe counter-intuitive read
The app's maintenance-mode status is a feature, not a bug…
Read the full takeSince the last report: Pedi QuikCalc 5 has entered a maintenance-only lifecycle, with no updates for over a year, creating a long-term vulnerability against more agile medical reference tools. The app's competitive narrative has shifted from highlighting niche utility to acknowledging the risks of stagnation in a market moving toward subscription-based, frequently updated platforms.
Bottom line
Maintaining the current clinical accuracy of the formulary will defend the app's position among established users, but the lack of active development leaves the user base vulnerable to more agile, frequently updated competitors.
Unlock 3 critical frictions, 3 market threats, 1 more prioritized move and the analyst’s take.
Access the full report for freeSources
- [1] App Store listing, source
Report last updated